Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maxwell B Sauder

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Journal of the American Academy of Dermatology|July 14, 2025
Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 studyAndrew Blauvelt, Petr Arenberger, Maxwell B Sauder, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 21, 2025
Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidanceKim A Papp, Luis Puig, Jennifer Beecker, et al.
International Journal of Dermatology|May 19, 2023
Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and managementRohan Mital, Tracey S Otto, Andrei Savu, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 21, 2023
Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)Sofia Genta, Katherine Lajkosz, Noelle R Yee, et al.
Lancet (London, England)|July 27, 2024
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trialsJonathan I Silverberg, Andreas Wollenberg, Adam Reich, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Journal of the American Academy of Dermatology|July 14, 2025
Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 studyAndrew Blauvelt, Petr Arenberger, Maxwell B Sauder, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 21, 2025
Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidanceKim A Papp, Luis Puig, Jennifer Beecker, et al.
International Journal of Dermatology|May 19, 2023
Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and managementRohan Mital, Tracey S Otto, Andrei Savu, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 21, 2023
Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)Sofia Genta, Katherine Lajkosz, Noelle R Yee, et al.
Lancet (London, England)|July 27, 2024
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trialsJonathan I Silverberg, Andreas Wollenberg, Adam Reich, et al.
Pageof 3